ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging In Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Guides & Guidelines

ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI Expert Consensus Recommendations for Multimodality Imaging In Cardiac Amyloidosis: Part 1 of 2-Evidence Base and Standardized Methods of Imaging

key information

source: Journal of Nuclear Cardiology

year: 2019

authors: Sharmila Dorbala, Yukio Ando, Sabahat Bokhari, Angela Dispenzieri, Rodney H Falk, Victor A Ferrari, Marianna Fontana, Olivier Gheysens, Julian D Gillmore, Andor W J M Glaudemans, Mazen A Hanna, Bouke P C Hazenberg, Arnt V Kristen, Raymond Y Kwong, Mathew S Maurer, Giampaolo Merlini, Edward J Miller, James C Moon, Venkatesh L Murthy, C Cristina Quarta, Claudio Rapezzi, Frederick L Ruberg, Sanjiv J Shah, Riemer H J A Slart, Hein J Verberne, Jamieson M Bourque

summary/abstract:

Cardiac amyloidosis is a form of restrictive infiltrative cardiomyopathy that confers significant mortality. Due to the relative rarity of cardiac amyloidosis, clinical and diagnostic expertise in the recognition and evaluation of individuals with suspected amyloidosis is mostly limited to a few expert centers. Electrocardiography, echocardiography, and radionuclide imaging have been used for the evaluation of cardiac amyloidosis for over 40 years. Although cardiovascular magnetic resonance (CMR) has also been in clinical practice for several decades, it was not applied to cardiac amyloidosis until the late 1990s. 
 
Despite an abundance of diagnostic imaging options, cardiac amyloidosis remains largely underrecognized or delayed in diagnosis. While advanced imaging options for noninvasive evaluation have substantially expanded, the evidence is predominately confined to single-center small studies or limited multicenter larger experiences, and there continues to be no clear consensus on standardized imaging pathways in cardiac amyloidosis. This lack of guidance is particularly problematic given that there are numerous emerging therapeutic options for this morbid disease, increasing the importance of accurate recognition at earlier stages.

organization: Brigham and Women's Hospital, Harvard Medical School, USA; Kumamoto University, Japan; Columbia University Medical Center/New York Presbyterian Hospital, Columbia University, USA; Mayo Clinic, USA; University of Pennsylvania, USA; University College London, United Kingdom; University Hospitals Leuven, Belgium; University Medical Center Groningen, The Netherlands; Cleveland Clinic, USA; University of Heidelberg, Germany; Foundation Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Italy; University of Pavia, Italy; Yale University School of Medicine, USA; Frankel Cardiovascular Center, USA; Alma Mater-University of Bologna, Italy; Boston Medical Center, USA; Northwestern University, USA; University of Amsterdam, The Netherlands; University of Virginia, USA

DOI: 10.1007/s12350-019-01760-6

read more full text

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close